{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:10:03Z","timestamp":1793736603373,"version":"4.6.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Primary aldosteronism is a common, yet highly underdiagnosed, cause of hypertension that leads to disproportionately high rates of cardiovascular disease. Hypertension plus hypokalemia is a guideline-recommended indication to screen for primary aldosteronism, yet the uptake of this recommendation at the population level remains unknown. We performed a population-based retrospective cohort study of adults \u226518 years old in Ontario, Canada, with hypertension plus hypokalemia (potassium &lt;3.5 mEq\/L) from 2009 to 2015 with follow-up through 2017. We measured the proportion of individuals who underwent primary aldosteronism screening via the aldosterone-to-renin ratio based upon hypokalemia frequency and severity along with concurrent antihypertensive medication use. We assessed clinical predictors associated with screening via Cox regression. The cohort included 26\u2009533 adults of which only 422 (1.6%) underwent primary aldosteronism screening. When assessed by number of instances of hypokalemia over a 2-year time window, the proportion of eligible patients who were screened increased only modestly from 1.0% (158\/15\u2009983) with one instance to 4.8% (71\/1494) with \u22655 instances. Among individuals with severe hypokalemia (potassium &lt;3.0 mEq\/L), only 3.9% (58\/1422) were screened. Among older adults prescribed \u22654 antihypertensive medications, only 1.0% were screened. Subspecialty care with endocrinology (hazard ratio [HR], 1.52 [95% CI, 1.10\u20132.09]), nephrology (HR, 1.43 [95% CI, 1.07\u20131.91]), and cardiology (HR, 1.39 [95% CI, 1.14\u20131.70]) were associated with an increased likelihood of screening, whereas age (HR, 0.95 [95% CI, 0.94\u20130.96]) and diabetes (HR, 0.66 [95% CI, 0.50\u20130.89]) were inversely associated with screening. In conclusion, population-level uptake of guideline recommendations for primary aldosteronism screening is exceedingly low. Increased education and awareness are critical to bridge this gap.<\/jats:p>","DOI":"10.1161\/hypertensionaha.121.18118","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T05:44:41Z","timestamp":1634535881000},"page":"178-186","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":113,"title":["Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study"],"prefix":"10.1161","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3559-3531","authenticated-orcid":true,"given":"Gregory L.","family":"Hundemer","sequence":"first","affiliation":[{"name":"Department of Medicine (Division of Nephrology) and the Ottawa Hospital Research Institute, University of Ottawa, ON, Canada (G.L.H., G.K., M.M.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Imsirovic","sequence":"additional","affiliation":[{"name":"Institute for Clinical Evaluative Sciences, Ottawa, Canada (H.I., M.M.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-9252","authenticated-orcid":true,"given":"Anand","family":"Vaidya","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA (A.V., N.Y.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Yozamp","sequence":"additional","affiliation":[{"name":"Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA (A.V., N.Y.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-3735","authenticated-orcid":true,"given":"R\u00e9mi","family":"Goupil","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Nephrology), H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, University of Montreal, QC, Canada (R.G., F.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Madore","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Nephrology), H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, University of Montreal, QC, Canada (R.G., F.M.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Agharazii","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Nephrology), CHU de Qu\u00e9bec-Universit\u00e9 Laval, Quebec City, Canada (M.A.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Knoll","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Nephrology) and the Ottawa Hospital Research Institute, University of Ottawa, ON, Canada (G.L.H., G.K., M.M.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish M.","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Nephrology) and the Ottawa Hospital Research Institute, University of Ottawa, ON, Canada (G.L.H., G.K., M.M.S.)."},{"name":"Institute for Clinical Evaluative Sciences, Ottawa, Canada (H.I., M.M.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0065"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.01.052"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000079505.25750.11"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.27.193"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.07.059"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30319-4"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.2003"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30367-4"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-4061"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa606"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14359"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2018.05.085"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2019.05.087"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.0254"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-4873"},{"key":"e_1_3_2_18_2","unstructured":"Statistics Canada. Table 17-10-0005-01 population estimates on july 1st by age and sex. Accessed April 19 2021. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710000501"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2007.08.012"},{"key":"e_1_3_2_21_2","first-page":"67","article-title":"Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.","volume":"10","author":"Levy AR","year":"2003","unstructured":"Levy, AR, O\u2019Brien, BJ, Sellors, C, Grootendorst, P, Willison, D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol. 2003;10:67\u201371.","journal-title":"Can J Clin Pharmacol"},{"key":"e_1_3_2_22_2","unstructured":"Statistics Canada. Table 17-10-0022-01 estimates of interprovincial migrants by province or territory of origin and destination annual. Accessed April 29 2019. https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1710002201"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.139279"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.071283"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00139"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2805"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12798"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.121.18118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:31:12Z","timestamp":1715581872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.121.18118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.121.18118"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.121.18118","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2021-07-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}